Ignite Creation Date:
2025-12-25 @ 12:14 AM
Ignite Modification Date:
2025-12-28 @ 12:49 PM
Study NCT ID:
NCT04454658
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-16
First Post:
2020-06-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
Sponsor:
AbbVie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-11-11
Start Date Type:
ACTUAL
Primary Completion Date:
2027-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-01
Completion Date Type:
ESTIMATED
First Submit Date:
2020-06-30
First Submit QC Date:
None
Study First Post Date:
2020-07-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-14
Last Update Post Date:
2025-07-16
Last Update Post Date Type:
ACTUAL